Technology

May 18, 2015.

AstraZeneca announces that it will invest $285 million in a new manufacturing facility in Sweden.

With acquisition of Oncaspar portfolio for leukemia from Sigma-Tau Finanziaria, Baxter BioScience adds an oncology infrastructure and biologic.

Juno Therapeutics announces that it will expand its cellular therapies pipeline with the acquisition of Stage Cell Therapeutics for €52.5 million.

Eli Lilly announces that it will establish a drug delivery and device center in Cambridge, Massachusetts.

Loreen M. Brown discusses how technology has influenced how healthcare teams function, from leveraging and delivering care to interacting with patients throughout the patient journey.

The agency publishes draft guidance answering industry questions about the Biologics Price Competition and Innovation Act.

May 13, 2015.

May 11, 2015.

A range of packages is available for industry partners to implement charity giving.

Novartis announces that its lung cancer drug, Zykadia, gained European Union approval.

Research from MediciGlobal shows that patients who actively sought clinical trial involvement through its online recruitment model had a 38% lower relative risk of drop out across four studies compared to those who were recruited by sites, with divergence across visits.

The US Court of Appeals granted Amgen’s request to block Novartis’ Neupogen biosimilar, Zarxio, from the US market until the court resolves litigation between the two companies.

May 7, 2015.

May 7, 2015.

May 6, 2015.

May 6, 2015.

May 6, 2015.

Alexion announces it will expand its rare disease pipeline with a definitive agreement to acquire Synageva.

Eleven of the leading US biosimilar developers have collaborated to form the Biosimilars Forum, a nonprofit organization formed to expand patient access to biosimilars.

May 5, 2015.

Dave Campbell offers some tactics that pharma leaders can implement to stem the continued global threat of counterfeit drugs.

April 30, 2015.

Perrigo rejected Mylan’s second proposal for an acquisition valued at more than $34 billion, saying that the offer was too low to consider.

Takeda Pharmaceutical agrees to pay $2.4 billion to settle lawsuits from patients and family members who said the diabetes drug Actos caused bladder cancer.

FDA releases long-awaited guidance documents regarding the assessment of biosimilarity.

April 28, 2015.

April 28, 2015.

April 27, 2015.

April 27, 2015.